在炎症性肠病患者中增加IL-39的合成和肠道表达
Gabriela Fonseca-Camarillo1,2, Janette Furuzawa-Carballeda3, Rafael Barreto-Zúñiga4
1Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, #15, Col. Belisario Domínguez Sección XVI, 14080, Mexico City, CP, Mexico.
Immunologic research
|November 16, 2023
概括
干白素-39 (IL-39) 在活性炎症性肠病 (IBD) 中被上调,包括性结肠炎和克罗恩病. 这种细胞因子可能作为IBD的炎症调解剂,表明潜在的治疗应用.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 介乐-39 (IL-39) 是一种包含IL-23p19和EBI3亚单元的细胞因子,与炎症调节有关.
- 在炎症性肠病 (IBD) 患者的肠道微环境中,IL-39的作用和表达仍然在很大程度上未被描述.
研究的目的:
- 研究IBD患者的肠道组织和血清中IL-39的表达和合成.
- 确定IL-39水平与性结肠炎 (UC) 和克罗恩病 (CD) 中的疾病活性或严重程度之间的相关性.
主要方法:
- 使用实时聚合酶链反应 (RT-PCR) 量化评估IL-39亚单元mRNA表达.
- 在肠道组织中通过免疫组织化学 (IHQ) 评估IL-39蛋白质合成.
- 使用酶相关免疫吸收试验 (ELISA) 测量血清IL-39水平.
主要成果:
- 相对mRNAIL-39的表达在活跃的UC和CD患者中明显升高,与缓解和健康对照患者相比.
- 增加IL-39表达,特别是IL-23p19亚单元,与组织学疾病活性相关.
- 免疫组织化学检查显示,在活跃疾病患者的肠壁多层上,IL-39的产生增加.
- 在被诊断为UC的患者中,血清IL-39水平升高.
结论:
- 这项研究提供了在活跃IBD患者中IL-39上调的第一个证据.
- IL-39可能在活性IBD的发病过程中起到关键的炎症调解作用.
- 这些发现表明IL-39是IBD管理的潜在治疗点.
相关概念视频
01:30Inflammatory Bowel Disease II: Crohn's Disease
256
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
256
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
146
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
146
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
190
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
190
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
337
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
337
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:29Inflammatory Bowel Disease IV: Pharmacological Management
132
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
132